Skip to main content
SpringerLink
Log in

RMI-81,582, a novel antipsychotic drug

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

RMI-81,582 (2-chioro-11-3-dimethylaminopropylidene morphanthridene), a potential antipsychotic agent, was administered to eight chronic and four acute male schizophrenics in an open label study. Ten of twelve patients improved, particularly those who were experiencing their first hospitalization, regardless of whether they met Research Diagnostic Criteria for acute or chronic schizophrenia. Significant improvement was noted on the Clinical Global Impressions and Brief Psychiatric Rating Scale. No extrapyramidal side effects were noted and other adverse reactions were few. Serum prolactin levels, a measure of antidopaminergic activity, were increased by low-moderate dosages of RMI-81,582 in seven of eleven patients. Four patients had no increase in serum prolactin with RMI-81,582. In six of the seven patients who developed increases in serum prolactin, prolactin levels returned to those characteristic of the placebo period as the dosage of RMI-81,582 was increased. With classical neuroleptics, serum prolactin levels increase as the dose increases up to approximately the equivalent of chlorpromazine 600 mg/day and then remain fairly constant. The pattern of serum prolactin response in both man and laboratory animals and the absence of extrapyramidal side effects suggest RMI-81,582 may have a clozapine-like action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Amsler, H. A., Teerenhovi, L., Barth, E., Hargula, K., Vuopio, P.: Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr. Scand. 56, 241–248 (1977)

    Google Scholar 

  • Angrist, B., Rotrosen, J., Aronson, M., Gershon, S.: A morphanthridine derivative in schizophrenic patients — lack of extrapyramidal symptoms. Curr. Ther. Res. Clin. Exp. 20, 94–99 (1976)

    Google Scholar 

  • Battegay, R., Cotar, B., Fleischhauer, J., Rauchfleisch, U.: Results and side effects of treatment with clozapine (LeponexGf). Compr. Psychiatry 18, 423–428 (1977)

    Google Scholar 

  • Bjerkenstedt, L., Eneroth, P., Harnryd, C., Sedvall, G.: Effects of Melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women. Arch. Psychiatr. Nervenkr. 224, 281–293 (1977a)

    Google Scholar 

  • Bjerkenstedt, L., Gullberg, B., Harnryd, C., Sedvall, G.: Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with Melperone or thiothixene. Arch. Psychiatr. Nervenkr. 224, 107–118 (1977b)

    Google Scholar 

  • Bjerkenstedt, L., Harnryd, C., Grimm, V., Gullberg, B., Sedvall, G.: A double-blind comparison of Melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch. Psychiatr. Nervenkr. 226, 157–172 (1978)

    Google Scholar 

  • Bowers, M. B., Jr., Heninger, G. R., Meltzer, H. Y.: Plasma and CSF dopamine metabolites in psychiatric patient: Effects of probenecid and haloperidol. In: Catecholamines: Basic and clinical frontiers. Vol. II. E. Usdin, I. J. Kopin, J. Barchas, eds., pp. 1893–1895. New York: Pergamon Press 1979

    Google Scholar 

  • Carlsson, A., Persson, T., Roos, B. E., Wålinder, J.: Potentiation of phenothiazines by α-methyltyrosine in treatment of chronic schizophrenia. Neural Transm. 33, 83–90 (1972).

    Google Scholar 

  • Carlsson, A., Roos, B.-E., Wålinder, J., Skott, A.: Further studies on the mechanism of antipsychotic action: potentiation of α-methyltyrosine of thioridazine effects in chronic schizophrenics. J. Neural Transm. 34, 125–132 (1973)

    Google Scholar 

  • Carlsson, A.: Does dopamine play a role in schizophrenia? Psychol. Med. 7, 585–597 (1977)

    Google Scholar 

  • Clemens, J. A., Smalstig, E. B., Sawyer, B. D.: Anti-psychotic drugs stimulate prolactin release. Psychopharmacologia (Berl.) 40, 123–127 (1974)

    Google Scholar 

  • Gianutsos, G., Moore, K. E.: Possible significance of clozapine-induced increase in brain dopamine. Res. Commun. Chem. Pathol. Pharmacol. 17, 29–39 (1977)

    Google Scholar 

  • Honigfeld, G., Klett, J.: Nurses observation scale for in patient evaluation (NOSIE). Clin. Psychol. 21, 65–71 (1965)

    Google Scholar 

  • Hwang, P., Guyda, H., Friesen, H.: A radioimmunoassay for human prolactin. Proc. Natl. Acad. Sci. USA 68, 1902–1906 (1971)

    Google Scholar 

  • Hyttel, J.: Effect of neuroleptics on the disappearance rate of 14C labelled catecholamines formed from 14C tyrosine in mouse brain. Pharm. Pharmacol. 26, 29–39 (1977)

    Google Scholar 

  • Lehmann, H. E., Ban, T. A., Deutsch, M.: An uncontrolled clinical study with EX 11-582A in the treatment of chronic schizophrenic patients. Psychopharmacol. Bull. 13, 7–9 (1977)

    Google Scholar 

  • Meltzer, H. Y., Daniels, S., Fang, V. S.: Clozapine increases rat serum prolactin levels. Life Sci. 17, 339–342 (1975)

    Google Scholar 

  • Meltzer, H. Y., Fang, V. S.: The effect of neuroleptics on serum prolactin levels in schizophrenic patients. Arch. Gen. Psychiatry 30, 279–286 (1976)

    Google Scholar 

  • Meltzer, H. Y., Goode, D. J., Fang, V. S.: The effect of psychotropic drugs on endocrine function. I. Neuroleptics, precursors and agonists. In: Psychopharmacology: A generation of progress. A. Lipton, A. DiMascio, K. F. Killam, eds., pp. 509–529. New York: Raven Press 1978

    Google Scholar 

  • Meltzer, H. Y., Goode, D. J. Schyve, P. M., Young, M. A., Fang, V. S.: Effect of clozapine on human serum prolactin levels. Arch. Gen. Psychiatry (in press, 1979)

  • Overall, J. E., Gorham, D. R.: The brief psychiatric rating scale (BPRS) Psychol. Rep. 10, 799–812 (1962)

    Google Scholar 

  • Pearl, D., van der, Kamp, H., Olsen, A. L., Greenberg, P. O., Armitage, S. G.: The effects of reserpine on schizophrenic patients. Arch. Neurol. Psychiatry 76, 198–204 (1956)

    Google Scholar 

  • Richardson-Merrill, Inc., Investigational Brochure, RMI-81,582, 1972

  • Seeman, P., Chau-Wong, M., Tedesco, J., Wong, K.: Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. USA 72, 4376–4380 (1975)

    Google Scholar 

  • Simpson, G. M., Zoubok, B., Lee, J. H.: An early clinical and toxicty trial of EX 11-582A in chronic schizophrenia. Curr. Ther. Res. 19, 87–93 (1976)

    Google Scholar 

  • Snyder, S. H., Banerjee, S. P., Yamamura, H. I., Greenberg, D.: Drugs, neurotransmitter, and schizophrenia. Science 184, 1243–1253 (1974)

    Google Scholar 

  • Weissman, A., Koe, B. K.: Behavioral effects of 1-α-methyltyrosine, an inhibitor of tyrosine hydrozylase. Life Sci. 4, 1037–1048 (1965)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Illinois State Psychiatric Institute, and Department of Psychiatry, University of Chicago Pritzker School of Medicine, 950 East 59th Street, 60637, Chicago, Illinois, USA

    Michael A. Young & Herbert Y. Meltzer

Authors
  1. Michael A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert Y. Meltzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, M.A., Meltzer, H.Y. RMI-81,582, a novel antipsychotic drug. Psychopharmacology 67, 101–106 (1980). https://doi.org/10.1007/BF00427603

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00427603

Key words

Search

Navigation